SecBot SecBot

DARE drug pipeline

Dare Bioscience, Inc. · 2 rated drugs
$0.6570
+2.0% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±2.8%
1-day, median of 1 event
IV rank
No data
No current options data
Rated drugs
2
1 mixed · 1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
◆ mixed
Impact
PhaseCommercial/Compounded Product (not FDA-approved drug)
Time to marketAlready available for dispensing (Q3 2026); revenue expected to begin in the current quarter.

DARE to PLAY sildenafil topical cream Updated Sep 13

What to watch

Watch for Q3 2026 earnings (likely November 2026) for the first DARE to PLAY dispensing and revenue figures, this will be the first real read on commercial traction. Also monitor Nasdaq listing compliance updates and any further dilutive financing, as the company's cash runway extends only into Q4 2026.

Bull case
  • Addresses a large, underserved market, female sexual dysfunction has no widely accepted FDA-approved treatment, creating a first-mover opportunity.
  • Analyst consensus is overwhelmingly bullish: 8 Buy/Strong Buy ratings vs 1 Hold, with a mean price target of $8.33 (over 1,000% implied upside from the ~$0.70 stock price).
  • As a compounded product (not an FDA-regulated new drug), DARE to PLAY avoids lengthy clinical trials and can generate revenue quickly once dispensing begins.
Bear case
  • Severe financial distress: cash burned from $24.7M to $12.6M in H1 2026, with negative working capital and stockholders' deficit, cash runway extends only into Q4 2026.
  • Active Nasdaq delisting risk with a hearing scheduled in late August 2026; stock trades near its 52-week low of $0.69.
  • Massive dilution overhang: a ~$6M August 2026 offering at $1.37/share plus warrants for up to 200% additional shares, and an S-1 registration effective September 2026 for further potential share sales.
● neutral
Impact
PhasePhase 2 (IND cleared, trial not yet initiated)
Time to marketUnknown — Phase 2 trial has not yet initiated. If successful, a registrational Phase 3 trial and FDA review would follow, likely putting potential approval several years out (2029+).

DARE-HPV Updated Sep 13

What to watch

DARE-HPV has no hard binary catalyst in the next ~12 months, the Phase 2 trial has not yet initiated enrollment. The stock's primary near-term driver is the company's survival (cash runway, Nasdaq compliance, dilution from the effective S-1), not DARE-HPV data. Watch for Phase 2 trial initiation press releases or partnership/licensing deals as potential catalysts, but the financial overhang dominates the risk/reward.

Bull case
  • Persistent high-risk HPV infection has no FDA-approved drug therapy, DARE-HPV addresses a large unmet need in women's health and could be first-in-class if successful.
  • The program is supported by ~$10M in non-dilutive ARPA-H funding, reducing the cash burden on the company.
  • Multiple institutional investors (Vanguard, BlackRock, State Street, Northern Trust) added or doubled their DARE positions in Q2 2026, signaling institutional interest.
Bear case
  • The company is in severe financial distress: cash dropped from $24.7M to $12.6M in H1 2026, with negative working capital and an active Nasdaq delisting risk.
  • A distressed ~$6M public offering in August 2026 at $1.37/share included massive warrant coverage (up to 200% of shares), creating severe dilution overhang. An S-1 registration became effective in September 2026, enabling further dilution.
  • DARE-HPV is at the earliest clinical stage (Phase 2 not yet initiated), no safety or efficacy data exist yet. The drug could fail to demonstrate any benefit.

Past FDA events & how the stock moved

1 events
DateDrugEvent1 day5 days
Feb 1, 2026DARE-HPVNDA filed−2.8%−6.6%